Veradermics, Incorporated (MANE)

Veradermics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	5.66	53.08	16.3
Cash & Short-Term Investments	15.14	53.08	16.3
Cash Growth	-	225.75%	-
Other Receivables	1.23	1.38	-
Receivables	1.23	1.38	-
Prepaid Expenses	2.07	1.04	1.22
Other Current Assets	0.27	0.04	0.05
Total Current Assets	18.71	55.54	17.56
Total Assets	18.8	55.54	17.56
Accounts Payable	1.99	2.25	1.85
Accrued Expenses	2.6	2.47	1.2
Total Current Liabilities	5.69	4.72	3.05
Long-Term Debt	-	-	0.79
Total Liabilities	5.71	4.72	3.84
Common Stock	0	0	0
Additional Paid-In Capital	1.36	0.75	0.5
Retained Earnings	-97.38	-49.23	-22.74
Comprehensive Income & Other	-2.47	-3.85	-0.89
Total Common Equity	-98.48	-52.33	-23.14
Shareholders' Equity	13.09	50.82	13.72
Total Liabilities & Equity	18.8	55.54	17.56
Total Debt	0.02	-	0.79
Net Cash (Debt)	15.12	53.08	15.51
Net Cash Growth	-	242.26%	-
Net Cash Per Share	20.39	72.03	21.05
Filing Date Shares Outstanding	0.75	0.74	0.74
Total Common Shares Outstanding	0.75	0.74	0.74
Working Capital	13.02	50.82	14.51
Book Value Per Share	-131.48	-71.01	-31.39
Tangible Book Value	-98.48	-52.33	-23.14
Tangible Book Value Per Share	-131.48	-71.01	-31.39

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q